

## **PROLIGHT SECURES THIRD PATENT IN EUROPE FOR PSYROS™**

**Prolight Diagnostics announces today that its third European patent for the Psyros single-molecule-counting technology has been granted in Europe by the European Patent Office (EPO), bringing the total number of patents granted in 2025 to three for the Psyros technology. The third patent is valid until 2042.**

“We are delighted that the EPO have granted another patent for the Psyros technology”, said Ulf Bladin, CEO of Prolight Diagnostics. “The relative speed at which our patents are being granted demonstrates the uniqueness of the technology and our strong freedom-to-operate.”

The Psyros technology uses photoactive reporter molecules to permanently bleach dark spots in a fluorescent layer, with each spot representing a single binding event. This patent protects a novel embodiment of the technology where light of two different wavelengths is used to generate the dark spots. The granted patent will have number EP 4 496 995, and the official mention of the grant will be published in European Patent Bulletin (25/52) on the 24<sup>th</sup> Dec 2025.

Prolight currently have six families of patent applications relating to the Psyros technology. The first five are currently in the national / regional phases in a range of territories worldwide. The sixth has just entered the PCT phase. Patents from the first two families were granted in Europe earlier this year. The family one patent was also granted earlier this year in Japan.

**For further information, please contact:**

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

**About Us**

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

## **Attachments**

**Prolight secures third patent in Europe for Psyros™**